1-20 of 24
cytotoxicity
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Kallesh D. Jayappa, Vicki L. Gordon, Christopher G. Morris, Briana Wilson, B. Dharmaveer Shetty, Konrad J. Cios, Puja C. Arora, Krista M. Isaac, Shekhar Saha, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Michael J. Weber
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3497–3510.
https://doi.org/10.1182/bloodadvances.2020003944
Published: 2021
Includes: Supplemental data
Journal Articles

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Hilma J. van der Horst, Anne T. Gelderloos, Martine E. D. Chamuleau, Esther C. W. Breij, Sonja Zweegman, Inger S. Nijhof, Marije B. Overdijk, Tuna Mutis
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2165–2172.
https://doi.org/10.1182/bloodadvances.2020003731
Published: 2021
Includes: Supplemental data
Journal Articles

The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma

Brittany C. Lipchick, Adam Utley, Zhannan Han, Sudha Moparthy, Dong Hyun Yun, Anna Bianchi-Smiraglia, David W. Wolff, Emily Fink, Liang Liu, Cristina M. Furdui, Jingyun Lee, Kelvin P. Lee, Mikhail A. Nikiforov
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1933–1946.
https://doi.org/10.1182/bloodadvances.2020002578
Published: 2021
Includes: Supplemental data
Journal Articles

A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells

David J. DiLillo, Kara Olson, Katja Mohrs, Thomas Craig Meagher, Kevin Bray, Olga Sineshchekova, Thomas Startz, Jessica Kuhnert, Marc W. Retter, Stephen Godin, Prachi Sharma, Frank Delfino, John Lin, Eric Smith, Gavin Thurston, Jessica R. Kirshner
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1291–1304.
https://doi.org/10.1182/bloodadvances.2020002736
Published: 2021
Includes: Supplemental data
Journal Articles

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Kodandaram Pillarisetti, Gordon Powers, Leopoldo Luistro, Alexander Babich, Eric Baldwin, Yingzhe Li, Xiaochun Zhang, Mark Mendonça, Nate Majewski, Rupesh Nanjunda, Diana Chin, Kathryn Packman, Yusri Elsayed, Ricardo Attar, François Gaudet
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4538–4549.
https://doi.org/10.1182/bloodadvances.2020002393
Published: 2020
Includes: Supplemental data
Journal Articles

AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys

Rebecca L. Goldstein, Ana Goyos, Chi-Ming Li, Petra Deegen, Pamela Bogner, Alexander Sternjak, Oliver Thomas, Matthias Klinger, Joachim Wahl, Matthias Friedrich, Benno Rattel, Edwin Lamas, Xiaoshan Min, Athena Sudom, Mozhgan Farshbaf, Angela Coxon, Mercedesz Balazs, Tara Arvedson
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4180–4194.
https://doi.org/10.1182/bloodadvances.2020002565
Published: 2020
Includes: Supplemental data
Journal Articles

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Clinical Trials & Observations
Michael A. Spinner, Alexey Aleshin, Marianne T. Santaguida, Steven A. Schaffert, James L. Zehnder, A. Scott Patterson, Christos Gekas, Diane Heiser, Peter L. Greenberg
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2768–2778.
https://doi.org/10.1182/bloodadvances.2020001934
Published: 2020
Includes: Supplemental data
Journal Articles

Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells

Xiaomei Wang, Daniel L. Jasinski, Jan L. Medina, David M. Spencer, Aaron E. Foster, J. Henri Bayle
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1950–1964.
https://doi.org/10.1182/bloodadvances.2020001510
Published: 2020
Includes: Supplemental data
Journal Articles

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression

Clinical Trials & Observations
Zachary J. Walker, Michael J. VanWyngarden, Brett M. Stevens, Diana Abbott, Andrew Hammes, Christophe Langouët-Astrie, Clayton A. Smith, Brent E. Palmer, Peter A. Forsberg, Tomer M. Mark, Craig T. Jordan, Daniel W. Sherbenou
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1628–1639.
https://doi.org/10.1182/bloodadvances.2019000122
Published: 2020
Includes: Supplemental data
Journal Articles

Chimeric antigen receptor–T cells with cytokine neutralizing capacity

Adrian H. J. Tan, Natasha Vinanica, Dario Campana
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1419–1431.
https://doi.org/10.1182/bloodadvances.2019001287
Published: 2020
Includes: Supplemental data
Journal Articles

Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia

Edward Abadir, Pablo A. Silveira, Robin E. Gasiorowski, Murari Ramesh, Adelina Romano, Ahmed H. Mekkawy, Tsun-Ho Lo, Karieshma Kabani, Sarah Sutherland, Geoffrey A. Pietersz, P. Joy Ho, Christian E. Bryant, Stephen R. Larsen, Georgina J. Clark
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1206–1216.
https://doi.org/10.1182/bloodadvances.2019001289
Published: 2020
Includes: Supplemental data
Journal Articles

A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia

Priyanka Nair-Gupta, Michael Diem, Dara Reeves, Weirong Wang, Robert Schulingkamp, Katrin Sproesser, Bethany Mattson, Bradley Heidrich, Mark Mendonça, Jocelin Joseph, Jocelyn Sendecki, Brad Foulk, Gerald Chu, Damien Fink, Qun Jiao, Sheng-Jiun Wu, Kathryn Packman, Yusri Elsayed, Ricardo Attar, François Gaudet
Journal: Blood Advances
Blood Adv (2020) 4 (5): 906–919.
https://doi.org/10.1182/bloodadvances.2019001188
Published: 2020
Includes: Supplemental data
Journal Articles

CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML

Bérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, Madeleine Suffiotti, Valentina Salvestrini, Tania Wyss, Giulia Vanoni, Dan Fu Ruan, Marianna Rossi, Alessandra Tozzo, Paolo Tentorio, Elena Bruni, Carsten Riether, Eva-Maria Jacobsen, Peter Jandus, Curdin Conrad, Manfred Hoenig, Ansgar Schulz, Katarzyna Michaud, Matteo Giovanni Della Porta, Silvia Salvatore, Ping-Chih Ho, David Gfeller, Adrian Ochsenbein, Domenico Mavilio, Antonio Curti, Emanuela Marcenaro, Alexander Steinle, Amir Horowitz, Pedro Romero, Sara Trabanelli, Camilla Jandus
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3674–3687.
https://doi.org/10.1182/bloodadvances.2018030478
Published: 2019
Includes: Supplemental data
Journal Articles

Human CD8 + Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice

Séverine Bézie, Béatrice Charreau, Nadège Vimond, Juliette Lasselin, Nathalie Gérard, Véronique Nerrière-Daguin, Frédérique Bellier-Waast, Franck Duteille, Ignacio Anegon, Carole Guillonneau
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3522–3538.
https://doi.org/10.1182/bloodadvances.2019000411
Published: 2019
Includes: Supplemental data
Journal Articles

Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia

Hyun Don Yun, Dawn K. Schirm, Martin Felices, Jeffrey S. Miller, Craig E. Eckfeldt
Journal: Blood Advances
Blood Adv (2019) 3 (16): 2448–2452.
https://doi.org/10.1182/bloodadvances.2019000064
Published: 2019
Journal Articles

Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia

Shaneice R. Mitchell, Karilyn Larkin, Nicole R. Grieselhuber, Tzung-Huei Lai, Matthew Cannon, Shelley Orwick, Pratibha Sharma, Yerdanose Asemelash, Pu Zhang, Virginia M. Goettl, Larry Beaver, Alice Mims, Vinay K. Puduvalli, James S. Blachly, Amy Lehman, Bonnie Harrington, Sally Henderson, Justin T. Breitbach, Katie E. Williams, Shuai Dong, Erkan Baloglu, William Senapedis, Karl Kirschner, Deepa Sampath, Rosa Lapalombella, John C. Byrd
Journal: Blood Advances
Blood Adv (2019) 3 (3): 242–255.
https://doi.org/10.1182/bloodadvances.2018024182
Published: 2019
Includes: Supplemental data
Journal Articles

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors

Sondra Downey-Kopyscinski, Ellen W. Daily, Marc Gautier, Ananta Bhatt, Bogdan I. Florea, Constantine S. Mitsiades, Paul G. Richardson, Christoph Driessen, Herman S. Overkleeft, Alexei F. Kisselev
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2443–2451.
https://doi.org/10.1182/bloodadvances.2018016360
Published: 2018
Includes: Supplemental data
Journal Articles

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells

Hyun Don Yun, Martin Felices, Daniel A. Vallera, Peter Hinderlie, Sarah Cooley, Michel Arock, Jason Gotlib, Celalettin Ustun, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2018) 2 (13): 1580–1584.
https://doi.org/10.1182/bloodadvances.2018018176
Published: 2018
Includes: Supplemental data
Journal Articles

Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation

Clinical Trials & Observations
Coco de Koning, Julie-Anne Gabelich, Jurgen Langenhorst, Rick Admiraal, Jurgen Kuball, Jaap Jan Boelens, Stefan Nierkens
Journal: Blood Advances
Blood Adv (2018) 2 (5): 565–574.
https://doi.org/10.1182/bloodadvances.2017015487
Published: 2018
Includes: Supplemental data
Journal Articles

Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists

Christopher T. Petersen, Mojibade Hassan, Anna B. Morris, Jasmin Jeffery, Kunhee Lee, Neera Jagirdar, Ashley D. Staton, Sunil S. Raikar, Harold T. Spencer, Todd Sulchek, Christopher R. Flowers, Edmund K. Waller
Journal: Blood Advances
Blood Adv (2018) 2 (3): 210–223.
https://doi.org/10.1182/bloodadvances.2017011254
Published: 2018
Includes: Supplemental data